Prescription Drugs: An Overview of Approaches to Negotiate Drug Prices Used by Other Countries & U.S. Private Payers & Federal Programs PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Prescription Drugs: An Overview of Approaches to Negotiate Drug Prices Used by Other Countries & U.S. Private Payers & Federal Programs PDF full book. Access full book title Prescription Drugs: An Overview of Approaches to Negotiate Drug Prices Used by Other Countries & U.S. Private Payers & Federal Programs by . Download full books in PDF and EPUB format.
Author:
Publisher: DIANE Publishing
ISBN: 9781422313602
Category :
Languages : en
Pages : 22
Get Book
Book Description
Author:
Publisher: DIANE Publishing
ISBN: 9781422313602
Category :
Languages : en
Pages : 22
Get Book
Book Description
Author: John E. Dicken
Publisher:
ISBN:
Category :
Languages : en
Pages : 17
Get Book
Book Description
Author: United States Government Accountability Office
Publisher: Createspace Independent Publishing Platform
ISBN: 9781719269094
Category :
Languages : en
Pages : 36
Get Book
Book Description
Prescription Drugs: An Overview of Approaches to Negotiate Drug Prices Used by Other Countries and U.S. Private Payers and Federal Programs
Author: United States. Congress. Senate. Committee on Finance
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 204
Get Book
Book Description
Author: National Academies of Sciences, Engineering, and Medicine
Publisher: National Academies Press
ISBN: 0309468086
Category : Medical
Languages : en
Pages : 235
Get Book
Book Description
Thanks to remarkable advances in modern health care attributable to science, engineering, and medicine, it is now possible to cure or manage illnesses that were long deemed untreatable. At the same time, however, the United States is facing the vexing challenge of a seemingly uncontrolled rise in the cost of health care. Total medical expenditures are rapidly approaching 20 percent of the gross domestic product and are crowding out other priorities of national importance. The use of increasingly expensive prescription drugs is a significant part of this problem, making the cost of biopharmaceuticals a serious national concern with broad political implications. Especially with the highly visible and very large price increases for prescription drugs that have occurred in recent years, finding a way to make prescription medicinesâ€"and health care at largeâ€"more affordable for everyone has become a socioeconomic imperative. Affordability is a complex function of factors, including not just the prices of the drugs themselves, but also the details of an individual's insurance coverage and the number of medical conditions that an individual or family confronts. Therefore, any solution to the affordability issue will require considering all of these factors together. The current high and increasing costs of prescription drugsâ€"coupled with the broader trends in overall health care costsâ€"is unsustainable to society as a whole. Making Medicines Affordable examines patient access to affordable and effective therapies, with emphasis on drug pricing, inflation in the cost of drugs, and insurance design. This report explores structural and policy factors influencing drug pricing, drug access programs, the emerging role of comparative effectiveness assessments in payment policies, changing finances of medical practice with regard to drug costs and reimbursement, and measures to prevent drug shortages and foster continued innovation in drug development. It makes recommendations for policy actions that could address drug price trends, improve patient access to affordable and effective treatments, and encourage innovations that address significant needs in health care.
Author: John E. Dicken
Publisher: DIANE Publishing
ISBN: 1437918557
Category : Medical
Languages : en
Pages : 16
Get Book
Book Description
Millions of individuals receive prescription drugs through fed. programs. The increasing cost of prescription drugs has put pressure to control drug spending on fed. programs such as the Fed. Employees Health Benefits Program (FEHBP), Medicare Part D, the VA, the DoD, and Medicaid. Prescription drug spending within the FEHBP in particular, which provides health and drug coverage to about 8 million fed. employees, retirees, and their dependents, has been a significant contributor to FEHBP cost and premium growth. This report describes approaches used by the FEHBP to control prescription drug spending and summarizes approaches used by other fed. programs. Illustrations.
Author: Peter J. Neumann
Publisher: Oxford University Press
ISBN: 0197512887
Category : Business & Economics
Languages : en
Pages : 273
Get Book
Book Description
The prescription drug market -- Proposed solutions for rising drug prices -- Measuring the value of prescription drugs -- Measuring drug value : whose job is it anyway? -- Institute for Clinical and Economic Review (ICER) -- Other US value assessment frameworks -- Do drugs for special populations warrant higher prices? -- Improving value measurement -- Aligning prices with value -- The path forward.
Author:
Publisher:
ISBN:
Category : Drugs
Languages : en
Pages : 234
Get Book
Book Description
On October 25,1999, the President directed the Secretary of Health and Human Services to study prescription drug costs and trends for Medicare beneficiaries. He asked that the study investigate: price differences for the most commonly used drugs for people with and without coverage; drug spending by people of various ages, as a percentage of income and of total health spending; and trends in drug expenditures by people of different ages, as a percentage of income and of total health spending. This report is the Department's response to that request. It represents the work of individuals and agencies throughout the Department, including the Agency for Healthcare Research and Quality (AHRQ), the Food and Drug Administration (FDA), the Health Care Financing Administration (HCFA), and the Office of the Assistant Secretary for Planning and Evaluation (ASPE).
Author:
Publisher: DIANE Publishing
ISBN: 9780788104688
Category : Drugs
Languages : en
Pages : 380
Get Book
Book Description
Analyzes the costs, risks, and economic rewards of pharmaceutical R&D and the impact of public policy on both costs and returns. Examines the rapid increase in pharmaceutical R&D that began in the 1980s in the light of trends in science, technology, drug discovery, and health insurance coverage; Government regulation; product liability; market competition; Federal tax policy; and Federal support of prescription drug research. 12 appendices, including a glossary of terms.
Author: United States. Congress. House. Committee on Oversight and Government Reform. Subcommittee on Federal Workforce, Postal Service, and the District of Columbia
Publisher:
ISBN:
Category : Business & Economics
Languages : en
Pages : 164
Get Book
Book Description
